FR2950350B1 - Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations - Google Patents

Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations

Info

Publication number
FR2950350B1
FR2950350B1 FR0904576A FR0904576A FR2950350B1 FR 2950350 B1 FR2950350 B1 FR 2950350B1 FR 0904576 A FR0904576 A FR 0904576A FR 0904576 A FR0904576 A FR 0904576A FR 2950350 B1 FR2950350 B1 FR 2950350B1
Authority
FR
France
Prior art keywords
exosomes
polypeptide
concerns
present
secretion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR0904576A
Other languages
English (en)
French (fr)
Other versions
FR2950350A1 (fr
Inventor
Robert Zaine El Abiddine Mamoun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite de Montpellier
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR0904576A priority Critical patent/FR2950350B1/fr
Priority to CA2775151A priority patent/CA2775151C/fr
Priority to US13/497,779 priority patent/US9611481B2/en
Priority to PCT/FR2010/052006 priority patent/WO2011036416A1/fr
Priority to JP2012530319A priority patent/JP5932647B2/ja
Priority to EP10769025.7A priority patent/EP2480672B8/fr
Publication of FR2950350A1 publication Critical patent/FR2950350A1/fr
Application granted granted Critical
Publication of FR2950350B1 publication Critical patent/FR2950350B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR0904576A 2009-09-24 2009-09-24 Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations Active FR2950350B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR0904576A FR2950350B1 (fr) 2009-09-24 2009-09-24 Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations
CA2775151A CA2775151C (fr) 2009-09-24 2010-09-23 Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations
US13/497,779 US9611481B2 (en) 2009-09-24 2010-09-23 Chimeric polynucleotides and polypeptides enabling the secretion of a polypeptide of interest in combination with exosomes and uses thereof
PCT/FR2010/052006 WO2011036416A1 (fr) 2009-09-24 2010-09-23 Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations
JP2012530319A JP5932647B2 (ja) 2009-09-24 2010-09-23 エキソソームに結合した目的のポリペプチドの分泌を可能にする新規キメラポリヌクレオチド及びポリペプチド、並びにその使用
EP10769025.7A EP2480672B8 (fr) 2009-09-24 2010-09-23 Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0904576A FR2950350B1 (fr) 2009-09-24 2009-09-24 Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations

Publications (2)

Publication Number Publication Date
FR2950350A1 FR2950350A1 (fr) 2011-03-25
FR2950350B1 true FR2950350B1 (fr) 2013-12-13

Family

ID=42107419

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0904576A Active FR2950350B1 (fr) 2009-09-24 2009-09-24 Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations

Country Status (6)

Country Link
US (1) US9611481B2 (enExample)
EP (1) EP2480672B8 (enExample)
JP (1) JP5932647B2 (enExample)
CA (1) CA2775151C (enExample)
FR (1) FR2950350B1 (enExample)
WO (1) WO2011036416A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2904382A1 (en) * 2013-03-15 2014-09-25 Novavax, Inc. Enhanced expression of picornavirus proteins
US10538570B2 (en) * 2013-09-30 2020-01-21 Northwestern University Targeted and modular exosome loading system
PL228341B1 (pl) * 2014-04-21 2018-03-30 Bio Ventures Inst Spolka Z Ograniczona Odpowiedzialnoscia Sposób uzyskiwania białka poliepitopowego oraz wektor DNA do realizacji tego sposobu
US10501733B2 (en) * 2015-02-27 2019-12-10 University Of Washington Polypeptide assemblies and methods for the production thereof
US10702581B2 (en) 2015-05-04 2020-07-07 Ilias Biologics Inc. Compositions containing protein loaded exosome and methods for preparing and delivering the same
JP2019528674A (ja) * 2016-09-30 2019-10-17 セレックス ライフ サイエンシズ，インコーポレーテッド タンパク質をロードしたエキソソームを含む組成物、並びにその調製及び送達のための方法
RS62863B1 (sr) 2018-11-16 2022-02-28 Codiak Biosciences Inc Konstruisane vanćelijske vezikule i njihove upotrebe
IT201900000651A1 (it) 2019-01-16 2019-04-16 Pastore Lucio Tecnologia di trasferimento genico
MX2021011242A (es) 2019-03-21 2022-01-19 Codiak Biosciences Inc Conjugados de vesícula extracelular y usos de estos.
BR112021020668A2 (pt) 2019-04-17 2022-01-11 Codiak Biosciences Inc Composições de exossomos e aav
EP3973969A4 (en) * 2019-09-02 2023-07-12 Kyungpook National University Industry-Academic Cooperation Foundation COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER, CONTAINING, AS ACTIVE PRINCIPLE, EXTRACELLULAR VESICLES EXPRESSING IL-2 ON THE SURFACE
WO2021144363A1 (en) 2020-01-14 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic reactivity of a peptide mimicking the glycan loop of flaviviruses envelope protein
JP7562682B2 (ja) * 2020-01-27 2024-10-07 マントラ バイオ，インコーポレイテッド キメラ小胞局在化部分を含む非天然発生の小胞、その産生方法、およびその使用
AU2021215935A1 (en) 2020-02-05 2022-08-25 Diadem Biotherapeutics Inc. Artificial synapses
WO2021184021A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting pmp22
WO2021216615A1 (en) * 2020-04-20 2021-10-28 The General Hospital Corporation Highly-networked coronavirus immunogen composition
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
CN116194462B (zh) * 2020-08-11 2025-07-18 庆北大学校产学协力团 选择性结合癌细胞来源外泌体的肽及其用途
EP3973985A1 (en) * 2020-09-29 2022-03-30 Ciloa Extracellular vesicles harboring a spike protein, nucleic acids for producing the same, and method of immunizing a subject against sars-cov-2 using the same
CN113480666B (zh) * 2021-08-13 2024-01-26 郑州伊美诺生物技术有限公司 Ca153融合蛋白及其制备方法和ca153检测质控品或校准品
US20250312464A1 (en) 2022-05-20 2025-10-09 Ciloa Reversible loading of proteins in the lumen of extracellular vesicles
WO2024097893A2 (en) * 2022-11-02 2024-05-10 Pioneer Biolabs, Llc Systems and methods for single cell detection of protein secretion
WO2024251819A1 (en) * 2023-06-05 2024-12-12 Ciloa Chimeric polypeptides, extracellular vesicles comprising the same, and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2454756C (en) 2001-08-17 2014-02-18 Anosys, Inc. Methods and compounds for the targeting of protein to exosomes
CA2479021A1 (en) 2002-03-14 2003-09-18 Anosys, Inc. Functionalization of t cell derived vesicles and use thereof for the preparation of immunogenic pharmaceutical compositions
JP4939926B2 (ja) 2003-02-14 2012-05-30 アノシス・インコーポレーテッド 抗体を生成し抗体レパートリーをスクリーニングするための方法とコンパウンド
FR2928926B1 (fr) 2008-03-18 2015-08-21 Centre Nat Rech Scient Polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leur utilisation pour la production de compositions immunogenes

Also Published As

Publication number Publication date
US9611481B2 (en) 2017-04-04
CA2775151A1 (fr) 2011-03-31
FR2950350A1 (fr) 2011-03-25
EP2480672A1 (fr) 2012-08-01
US20120321653A1 (en) 2012-12-20
CA2775151C (fr) 2019-01-22
EP2480672B8 (fr) 2017-03-22
WO2011036416A1 (fr) 2011-03-31
JP2013505713A (ja) 2013-02-21
JP5932647B2 (ja) 2016-06-08
EP2480672B1 (fr) 2016-12-28

Similar Documents

Publication Publication Date Title
FR2950350B1 (fr) Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations
AU2017248555B2 (en) Closed nucleic acid structures
MX2016011495A (es) Composicion y metodo para estabilizar acidos nucleicos en muestras biologicas.
PH12012502272A1 (en) Biological materials related to her3
ZA201902654B (en) In vitro and cell based assays for measuring the activity of botulinum neurotoxins
MX2016003945A (es) Composiciones y formulaciones para la prevencion y tratamiento de la diabetes y la obesidad y los metodos de produccion y uso en el control de la glucosa y calorias.
EP2470670A4 (en) COAGULATION FACTOR VII COMPOSITIONS AND METHODS OF PREPARATION AND USE THEREOF
MX373485B (es) Miembros de unión al factor de necrosis tumoral (tnf) alfa.
WO2009120374A3 (en) Methods and compositions for nucleic acid sample preparation
EA201171220A1 (ru) Мутанты fgf21 и их применение
MX2010004179A (es) Anticuerpos anti-amiloide, composiciones, metodos y usos.
EP2571531A4 (en) STABILIZED FIBRONES-INDUCTIVE COMPOSITIONS AND METHODS THEREFOR AND APPLICATIONS THEREOF
UA101301C2 (ru) ВЫДЕЛЕННОЕ АНТИТЕЛО ПРОТИВ IL-23pl 9 И ЕГО ПРИМЕНЕНИЕ
MY156286A (en) Human il-23 antigen binding proteins
UY32477A (es) Proteínas de unión a il-17
MX392780B (es) Polinucléotidos que condifican anticuerpos de oncostatina m humana
BR112012017345A2 (pt) "composições e métodos de pgl para a produção aumentada de isopreno e outros produtos com 6-fosfogliconolactonase (pgl)"
WO2012135805A3 (en) Delivery and formulation of engineered nucleic acids
EP4273238A3 (en) Compositions comprising polypeptides having xylanase activity and polypeptides having arabinofuranosidase activity
PH12012500816A1 (en) Modified oil encapsulating proteins and uses thereof
MX2009004243A (es) Nuevas proteinas h5, moleculas de acido nucleico y vectores que las codifican y su uso medicinal.
FI20115328A0 (fi) Uusia kutinaaseja, niiden tuottaminen ja käytöt
ATE549410T1 (de) Kontrollierte aktivierung von nicht-ltr- retrotransposonen bei säugetieren
WO2011085134A8 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer
WO2010009227A3 (en) Recombinant pokeweed antiviral proteins, compositions and methods related thereto

Legal Events

Date Code Title Description
TQ Partial transmission of property
PLFP Fee payment

Year of fee payment: 8

TQ Partial transmission of property

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (, FR

Effective date: 20170510

Owner name: UNIVERSITE DE MONTPELLIER, FR

Effective date: 20170510

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17